These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 334065)
21. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099 [TBL] [Abstract][Full Text] [Related]
22. A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in turkey from cutaneous lesions. Kantarcioglu AS; Yücel A Med Mycol; 2002 Oct; 40(5):519-23. PubMed ID: 12462532 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of synergistic interactions between amphotericin B and flucytosine. Beggs WH J Antimicrob Chemother; 1986 Apr; 17(4):402-4. PubMed ID: 3519560 [No Abstract] [Full Text] [Related]
24. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia. Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164 [TBL] [Abstract][Full Text] [Related]
26. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592 [TBL] [Abstract][Full Text] [Related]
27. Synergism of polyene antibiotics with 5-fluorocytosine. Polak A Chemotherapy; 1978; 24(1):2-16. PubMed ID: 338264 [TBL] [Abstract][Full Text] [Related]
28. Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice. Gadebusch HH; Pansy F; Klepner C; Schwind R J Infect Dis; 1976 Nov; 134(5):423-7. PubMed ID: 792355 [TBL] [Abstract][Full Text] [Related]
29. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Block ER; Jennings AE; Bennett JE Antimicrob Agents Chemother; 1973 Oct; 4(4):392-5. PubMed ID: 4598611 [TBL] [Abstract][Full Text] [Related]
31. [Further experimental data on clotrimazole: effectiveness against Cryptococcus neoformans, Sporothrix schenkii and Blastomyces dermatitidis Gilchrist]. Barfuss T; Seeliger HP; Plempel M Mykosen; 1975 May; 18(5):221-32. PubMed ID: 1099444 [No Abstract] [Full Text] [Related]
32. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B. Banerjee D; Burkard L; Panepinto JC PLoS One; 2014; 9(1):e87246. PubMed ID: 24498052 [TBL] [Abstract][Full Text] [Related]
34. Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Bava AJ; Negroni R Eur J Epidemiol; 1992 May; 8(3):422-6. PubMed ID: 1327864 [TBL] [Abstract][Full Text] [Related]
35. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome? Viviani MA; Esposto MC; Cogliati M; Tortorano AM J Chemother; 2003 Apr; 15(2):124-8. PubMed ID: 12797387 [TBL] [Abstract][Full Text] [Related]
36. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Fromtling RA; Abruzzo GK; Bulmer GS Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339 [TBL] [Abstract][Full Text] [Related]
37. [Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine]. Tanaka K; Kohno S; Maesaki S; Mitsutake K; Miyazaki H; Miyazaki T; Tomono K; Kaku M; Koga H; Hara K Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1528-33. PubMed ID: 8121088 [TBL] [Abstract][Full Text] [Related]
38. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811 [TBL] [Abstract][Full Text] [Related]
39. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Odds FC Antimicrob Agents Chemother; 1982 Nov; 22(5):763-70. PubMed ID: 6295266 [TBL] [Abstract][Full Text] [Related]
40. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Larsen RA; Bauer M; Thomas AM; Graybill JR Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]